Schüklenk U, Philpott S. International research ethics. In LaFollette H, Deigh J, Stroud S, LaFollette E (eds). 2013. International Encyclopedia of Ethics. Hoboken, NJ: Wiley-BlackwelPapers:
Flanigan B, Philpott S, Strosberg M. Protection of human participants enrolled in critical care research trials. Journal of Intensive Care Medicine 2011; in press.
Purdy S, Aagaard AW, Philpott S. The review, approval, and marketing of biosimilars in the United States. Part 2: Ethical issues. BioProcess International 2011; 9(1): 14-19.
Philpott S. (Un)Risky business: Adolescents and HIV prevention trials. American Journal of Bioethics 2011; in press.
Philpott S, McGrory E, Hankins C, Paxton L, Heise L, the Participants in the 2009 GCM/CDC/UNAIDS Consultation on Standards of Prevention in HIV Prevention Trials. Establishing clear standards of prevention in HIV prevention trials. Journal of Medical Ethics 2011; 27(4): 244-8.
Schüklenk U, Philpott S. AIDS: The time for changes in law and policy is now. International Journal of Law in Context 2011; in press.
Philpott S, Baker R. Why Avandia proves bio pharma needs stronger ethical standards. Bioethics 2010; 24(8): ii-iii.
Philpott S, Schüklenk U. Medical research that never should have taken place. Bioethics Forum 2010; May 5. Available online at http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=4626&blogid=140.
Philpott S, West Slevin K, Shapiro K, Heise L. Impact of donor-imposed requirements and restrictions on standards of prevention and access to care in HIV prevention trials. Public Health Ethics 2010;3(3):220-8.
Aagaard AW, Prudy S, Philpott S. The review, approval, and marketing of biosimilars in the United States. Part 1: Safety and regulatory issues. BioProcess International 2010; 8(11): 12-20.